• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21721 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2011     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Pharyngeal pH monitoring by Dx-pH measurement system]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pharmacotherapeutic interventions - Evidence report on the S3 guideline "Cannabis-related disorders"]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Pharmacologically-induced voluntary interruption of pregnancy]
2002     Basque Office for Health Technology Assessment (OSTEBA) [Pharmacological treatment of migraines. Qualitative study]
2020     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Pharmacological treatment of common pain conditions in older persons]
2012     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Pharmacological treatment for controlled ovarian hyperstimulation in vitro fertilization]
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Pharmacological interventions in forensic psychiatry]
2010     Gesundheit Osterreich GmbH (GOeG) [Pharmacological interactions between acetylcholinesterase inhibitors for treatment of dementia and further drugs occurring in patients of advanced age]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Pharmacogenomics bias - systematic distortion of study results by genetic heterogeneity]
2013     The Netherlands Organisation for Health Research and Development (ZonMw) [Pharmacogenetic testing in the clinical setting: is screening for TPMT genotype a cost-effective treatment strategy? The first prospective randomized controlled trial within the Dutch health care system]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Pharmacogenetic test (Neurofarmagen®) to assess the potential response to drugs and adverse effects in patients with neuropsychiatric disorders]
2015     Gesundheit Osterreich GmbH (GOeG) [Pharmaceutical stroke prevention in atrial fibrillation]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Volanesorsen]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Tisagenlecleucel (reassessment after expiry: diffuse large B-cell lymphoma)]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Pegvaliase]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Mexiletine]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Luspatercept (β-thalassaemia)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Imlifidase (desensitisation in kidney transplantation)]
2016     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Idebenone]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Glycerol phenylbutyrate (New Therapeutic Indication: Urea cycle disorders in infants aged 0 to < 2 months)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Glasdegib (acute myeloid leukaemia (AML), combination with cytarabine (LDAC))]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Givosiran (acute hepatic porphyria, ≥ 12 years)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Fenfluramine (Dravet syndrome, ≥ 2 years)]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Burosumab (reassessment after the deadline: hypophosphataemia)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Bulevirtide (chronic hepatitis delta virus (HDV) infection)]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Betibeglogene autotemcel (β-thalassaemia) (treatment costs)]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Bedaquiline (new therapeutic indication: multi-drug-resistant pulmonary tuberculosis, 12 to < 18 years)]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Axicabtagene ciloleucel]
2019     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Axicabtagene ciloleucel (PMBCL)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Autologous anti-CD19-transduced CD3+ cells (mantle cell lymphoma, pretreated patients)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Atidarsagen autotemcel (metachromatic leukodystrophy with biallelic mutation in the ARSA gene)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Amikacin (Mycobacterium avium complex pulmonary infections)]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Afamelanotide (Reassessment after the deadline: Phototoxicity in erythropoietic protoporphyria (EPP))]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Phakic intraocular lenses for high-grade myopia]
2006     The Netherlands Organisation for Health Research and Development (ZonMw) [PGS for aneuploidies in IVF]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [PET/CT scan for solitary pulmonary nodule and non-small cell lung cancer]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [PET-CT: needs assessment for planning]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [PET-CT in patients with head and neck cancer diagnosis]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [PET-CT evaluative registries in Madrid and Catalunya]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [PET scan - accuracy for Hodgkin's Disease]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab/trastuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab/trastuzumab (breast cancer, neoadjuvant) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab/trastuzumab (breast cancer, first line) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab/trastuzumab (breast cancer, adjuvant) - Benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab (breast cancer) - Addendum to Commission A18-41]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab - Addendum to Commission A15-34]
2020     National Committee for Technology Incorporation (CONITEC) [Personal frequency modulation system for hearing-impaired students at any age and at any academic level]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Peritoneal dialysis versus in-center hemodialysis: benefit, risk, cost and preferences]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Peritoneal dialysis versus hemodialysis for end stage renal disease]
2011     The Swedish Council on Health Technology Assessment (SBU) [Peripherally Inserted Central Venous Catheter (PICC)]
2009     Committee for New Health Technology Assessment (CNHTA) [Peripheral nerve stimulation]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Peripheral electrical nerve stimulation (PENS) therapy as treatment for refractory chronic neuropathic pain in adults: evaluation of safety, efficacy, clinical effectiveness, and cost-effectiveness]
2007     The Swedish Council on Health Technology Assessment (SBU) [Peripheral arterial disease - diagnosis and treatment]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Perioperative strategy in colonic surgery; laparoscopy and/or fast track multimodal management versus standard care]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Perioperative antibiotics for prevention of infections in arterial reconstructions with vascular prostheses]
2008     Andalusian Health Technology Assessment Area (AETSA) [Perfusion MR Imaging in differentiating brain gliomas. Meta-analysis and economic assessment]
2008     Andalusian Health Technology Assessment Area (AETSA) [Perfusion MR Imaging in differentiating brain gliomas. Meta-analysis and economic assessment]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Performance of specialised breast technicians in diagnostic breast imaging]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [PERFECT (D): primary care electronic referrals: focus on efficient consultation using telemedicine in dermatology]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneuous left atrial appendage closure for the prevention of thrombo-embolic events in patients with atrial fibrillation]
2010     The Regional Health Technology Assessment Centre (HTA-centrum) [Percutaneuos transcatheter closure of patent foramen ovale]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Percutaneously implanted interatrial shunt for the treatment of heart failure - Assessment according to §137h Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Percutaneously implanted interatrial shunt for the treatment of heart failure - Addendum to commission H20-06]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Percutaneous vertebroplasty in the treatment of osteoporotic vertebral fractures]
2010     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Percutaneous vertebroplasty as a treatment for osteoporotic vertebral fractures - a health technology assessment]
2011     The Swedish Council on Health Technology Assessment (SBU) [Percutaneous vertebroplasty and balloon kyphoplasty in treating painful osteoporotic vertebral compression fractures]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous transluminal septal myocardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy (HOCM)]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous transluminal coronary angioplasty (PTCA) with paclitaxel-coated drug-eluting balloon (DEB). Update 2013]
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB). 2nd Update 2016]
2014     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous transluminal angioplasty (pta) with drug eluting stents in peripheral arterial disease, upper limb and thorax]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous transluminal angioplasty (PTA) of periphery arteries with drug-eluting balloon (DEB)]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous transluminal angioplasty (PTA) of peripheral arteries with drug-eluting balloon (DEB)]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous transcatheter closure of prosthetic mitral and aortic paravalvular leaks]
2009     Committee for New Health Technology Assessment (CNHTA) [Percutaneous tracheostomy dilator]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Percutaneous tibial nerve stimulation for the treatment of overactive bladder]
2021     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Percutaneous repair systems for tricuspid valve insufficiency by annuloplasty]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous repair of mitral regurgitation with the MitraClip]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous repair of mitral regurgitation with the MitraClip]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Percutaneous pulmonary valve insertion for patients needing right ventricular outflow reintervention]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Percutaneous Mitral Valve Repair System (MitraClip®) for mitral valve insufficiency]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous left atrial appendage closure]
2023     Canary Health Service [Percutaneous ethanol injection in thyroid nodular pathology and metastatic cervical adenopathies]
2011     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Percutaneous coronary intervention with optimal medical therapy vs. optimal medical therapy alone for patients with stable angina pectoris]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous coronary intervention for chronic total occlusion]
2009     Committee for New Health Technology Assessment (CNHTA) [Percutaneous cement injection plasty of metastatic bone tumor]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Percutaneous cement discoplasty for the treatment of degenerative scoliosis in the elderly]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous aortic valve replacement with a side note to hybrid operating rooms]
2010     Institute for Clinical Effectiveness and Health Policy (IECS) [Percutaneous aortic valve replacement for aortic stenosis]
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous aortic valve replacement (TAVI) in Austria. Part 2: Data analysis]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous aortic valve replacement - 2nd Update 2010]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Percutaneous acrylic vertebroplasty for the treatment of vertebral fractures]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel (partial-onset seizures) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel (generalized epilepsy) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel (epilepsy) - Benefit assessment according to §35a Social Code Book (SGB) V]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]